BCM
BIOR

Bluefin Capital Management’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Bluefin Capital Management’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-135
Closed -$4.45K – 556
2022
Q4 		$4.45K Hold
135
– – ﹤0.01% 381
2022
Q3 		$16K Buy
135
+11
+9% +$1.98K ﹤0.01% 442
2022
Q2 		$22K Sell
124
-116
-48% -$24.5K ﹤0.01% 461
2022
Q1 		$70K Buy
240
+42
+21% +$15.9K 0.01% 439
2021
Q4 		$104K Buy
+198
New +$142K 0.01% 619

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bluefin Capital Management's BIOR Position: Q1 2023 in Review

Bluefin Capital Management sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2023, closing a stake of 135 shares — an estimated $4.45K sold.

Bluefin Capital Management first reported a position in BIOR in Q4 2021 and held it in 5 quarters. The position peaked at $104K in Q4 2021. 30 funds tracked by Wall St. Rank hold BIOR as of Q1 2023.

  • Bluefin Capital Management reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bluefin Capital Management sold 135 Biora Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4.45K.
  • Bluefin Capital Management first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
  • Bluefin Capital Management's Biora Therapeutics, Inc. Common Stock position peaked at $104K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Bluefin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.